17th Apr 2020 10:14
(Alliance News) - 4D Pharma PLC on Friday reported encouraging results from the Blautix phase II study data, which was for evaluating the safety and efficacy or repeated oral doses in adults with irritable bowel syndrome.
The pharmaceutical firm also announced the appointment of Axel Glasmacher as non-executive chair with immediate effect.
He will be replacing David Norwood, who is stepping down from his role after six years since 2014, but will remain in the company as a non-executive director.
Glasmacher's most recent executive role was as senior vice president and head of Clinical Research & Development for Hematology Oncology at Celgene, which is part of US biopharmaceutical firm Bristol-Myers Squibb Co.
The phase II, randomised, double blind, placebo-controlled multicentre study of Blautix was specifically for irritable bowel syndrome subtypes C and D.
Interim analysis of the study which involved 246 patients revealed that Blautix has a safety profile comparable to placebo with no increased adverse effects, and that the study was not futile, encouraging 4D Pharma to continue analysing the full trial data.
The group expects to report on the full data in the third quarter of 2020.
"The interim analysis of the Blautix phase II results in IBS is encouraging. IBS is a disease that causes significant morbidity and has a high unmet medical need. 4D Pharma identified the potential of the live biotherapeutic Blautix as a new approach to treat IBS and address both IBS-C and IBS-D with the same therapy. The interim analysis supports and informs 4D Pharma's future development and commercialisation plans with partners," said Chief Scientific Officer Alex Stevenson.
Shares in 4D Pharma were down 2.1% at 38.00 pence on Friday in London.
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L